Searching News Database: POZEN
HSMN NewsFeed - 1 Jun 2021
Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors
Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors
HSMN NewsFeed - 4 Apr 2016
Nuvo Pharmaceuticals(TM) Inc. Announces Appointment of Vice President, Business Development
Nuvo Pharmaceuticals(TM) Inc. Announces Appointment of Vice President, Business Development
HSMN NewsFeed - 1 Jun 2015
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
HSMN NewsFeed - 14 May 2014
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
HSMN NewsFeed - 19 Nov 2013
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
HSMN NewsFeed - 22 Mar 2012
POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540
POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540
HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
HSMN NewsFeed - 14 Apr 2010
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
HSMN NewsFeed - 14 Sep 2009
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 29 Jan 2009
POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
HSMN NewsFeed - 15 Jan 2008
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
HSMN NewsFeed - 5 Oct 2007
POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days
POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days
HSMN NewsFeed - 13 Jun 2007
OSI Pharmaceuticals Announces the Election of Kenneth B. Lee, Jr. to Its Board
OSI Pharmaceuticals Announces the Election of Kenneth B. Lee, Jr. to Its Board
HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Additional items found! 33
Members Archive contains
33 additional stories matching:
POZEN
(Password required)
POZEN
(Password required)